Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Shire PLC (NASDAQ:SHPG)

199.57
Delayed Data
As of 3:59pm ET
 -0.65 / -0.32%
Today’s Change
147.60
Today|||52-Week Range
231.32
-2.65%
Year-to-Date
Third Value Fund Avenue Buys 3 Stocks in 3rd Quarter
10:40am / GuruFocus News - Paid Partner Content
Mairs and Power Buys Walt Disney, Exits Baxalta
Sep 27 / GuruFocus News - Paid Partner Content
Momenta to Regain Rights to Humira Biosimilar from Shire
9:52am / Zacks.com - Paid Partner Content
Shire's Immunodeficiency Treatment Cuvitru Gets FDA Approval
Sep 15 / Zacks.com - Paid Partner Content
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter
Sep 27 / GuruFocus News - Paid Partner Content
 

Today’s Trading

Previous close200.22
Today’s open199.32
Day’s range197.92 - 200.49
Volume598,393
Average volume (3 months)1,980,371
Market cap$60.2B
Dividend yield0.40%
Data as of 3:59pm ET, 09/28/2016

Growth & Valuation

Earnings growth (last year)-61.89%
Earnings growth (this year)+10.34%
Earnings growth (next 5 years)+13.91%
Revenue growth (last year)+6.79%
P/E ratio32.4
Price/Sales6.33
Price/Book4.02

Competitors

 Today’s
change
Today’s
% change
ABTAbbott Laboratories-0.04-0.09%
REGNRegeneron Pharmaceut...-2.35-0.56%
CELGCelgene-1.57-1.46%
AZNAstraZeneca+0.21+0.62%
Data as of 4:02pm ET, 09/28/2016

Financials

Next reporting dateOctober 28, 2016
EPS forecast (this quarter)$3.25
Annual revenue (last year)$6.4B
Annual profit (last year)$1.3B
Net profit margin20.84%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Executive Director
Flemming Ornskov
Chief Financial Officer &
Executive Director
Jeffrey Poulton
Corporate headquarters
Dublin, Dublin

Forecasts

Search for Jobs